Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema.

Khanani, Arshad M; Patel, Sunil S; Gonzalez, Victor H; Moon, Suk J; Jaffe, Glenn J; Wells, John A; Kozma, Petra; Dugel, Pravin U; Maturi, Raj K

Khanani, Arshad M; Patel, Sunil S; Gonzalez, Victor H; Moon, Suk J; Jaffe, Glenn J; Wells, John A; Kozma, Petra; Dugel, Pravin U; Maturi, Raj K.

Afiliación

Khanani AM; Reno School of Medicine, University of Nevada, Reno, Nevada.
Patel SS; Sierra Eye Associates, Reno, Nevada.
Gonzalez VH; Ophthalmology Specialists of Texas, PLLC, and Integrated Clinical Research, LLC, Abilene, Texas.
Moon SJ; Valley Retina Institute, McAllen, Texas.
Jaffe GJ; Center for Retina & Macular Disease, Haines City, Florida.
Wells JA; Department of Ophthalmology, Duke University, Durham, North Carolina.
Kozma P; Palmetto Retina Center, Columbia, South Carolina.
Dugel PU; Oxurion NV, Leuven, Belgium.
Maturi RK; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.

Ophthalmol Sci ; 1(3): 100040, 2021 Sep.

Article en En | MEDLINE | ID: mdl-36247818

Palabras clave

AE, adverse event; BCVA, best-corrected visual acuity; CI, confidence interval; CST, central subfield thickness; DLT, dose-limiting toxicity; DME; DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluorescein angiography; Integrin antagonist; Intravitreal injection; NPDR, nonproliferative diabetic retinopathy; Phase 1; RGD, arginine-glycine-aspartic acid; SD-OCT, spectral-domain OCT; THR-687; VEGF, vascular endothelial growth factor

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Ophthalmol Sci Año: 2021 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google